SPOTLIGHT -
March 18th 2023
From an update on at-home ketamine therapy to the psychopharmacologic treatment of bipolar depression, here are highlights from the week in Psychiatric Times.
March 15th 2023
What is the best evidence-based medication treatment for acute bipolar II depression?
Study results show that the therapy activates serotonin (5-HT) and improves stress-coping ability.
March 13th 2023
The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.
March 11th 2023
Catch up on the latest CMEs in Psychiatric Times.
Neuromodulation Device for Depression Granted Breakthrough Device Designation
Transcranial direct current stimulation for depression.
Read More
Lithium: A Narrative Overview and Future Frontiers
Lithium: what’s its history and where do we still need more information?
Addressing Unmet Needs and Clinical Challenges in MDD
Here are 9 things you need to know about the clinical management of major depressive disorder.
“I’m Just So Tired”: Fatigue in a Medically Complicated Patient
Fatigue is a very common physical complaint. What therapeutic options are available?
The Week in Review: February 6-10
From the impact of patients’ overdose deaths on physicians to addressing America’s mental health crisis, here are highlights from the week in Psychiatric Times.
Depression in the African American Community
“We are not exempt from these diseases. We have to speak up.”
Treatment Resistant: Is It a Misnomer?
"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."
Rx Evolution: An Ununified Model of MDD and Pharmacological Paradigms
The Week in Review: January 23-27
From special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community, here are highlights from the week in Psychiatric Times.
Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder
SPL026 with supportive therapy sees positive results in patients with major depressive disorder.
The Week in Review: January 16-20
From a new FDA approval to treating “New Year depression” in patients, here are highlights from the week in Psychiatric Times.
CRP as a Biomarker of Antidepressant Efficacy
Is inflammation a biomarker of antidepressant efficacy? Researchers analyzed blood CRP levels as a predictor of response to antidepressants.
How to Navigate and Treat ‘New Year Depression’ in Your Patients
There may not be a diagnosis for ‘New Year Depression,’ about 10% to 20% of individuals in the US may get a milder form of these winter blues.
Potentially Treatable Metabolic Abnormalities in Patients with Treatment-Resistant Depression
Metabolic depression? Researchers performed a metabolomic evaluation of patients with treatment-resistant depression.
Keep the Cart Behind the Horse: Privilege and Responsibility as a Provider
Remember to keep the cart behind the horse while practicing medicine.
The Week in Review: December 26-30
From new advances in the treatment of postpartum depression to digital therapeutics for the treatment of ADHD in children, here are highlights from the week in Psychiatric Times.
The Year in CMEs
Revisiting the CME articles featured in Psychiatric Times in 2022.
The Week in Review: December 19-23
From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.
Cariprazine FDA-Approved as Adjunctive Therapy to Antidepressants
Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.
The Week in Review: December 5-9
From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.
Identifying the Symptom of Worthlessness to Prevent Suicide in Adolescents With ADHD
Screening for the symptom of worthlessness could save your adolescent patient’s life…
Rolling NDA Submission of Zuranolone for MDD, PPD is Completed
This latest submission completes the FDA filing that was initiated in May.
Meta-Analysis of Intravenous vs Intranasal Ketamine
Does route of administration affect antidepressant efficacy of ketamine? Researchers performed a meta-analysis of trials comparing intravenous and intranasal administration.
The Week in Review: November 28-December 2
From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.
Hooked on Hype? A Critical Examination of Recent Anti-Antidepressant Reporting
Here’s why most of the claims recently made about antidepressants in Newsweek are wrong.
Phase 1 Study of Apimostinel for Depression Doses First Participants
The drug is in development for the treatment of acute depressive disorders and depression with suicidality.
Thinking Beyond the Guidelines: Evidence-Based Novel Therapies for Bipolar Depression
In this CME article, learn how to apply novel treatment approaches for patients with bipolar depression.
Psychiatric Times™ Conference: Clinical Pearls for Treating MDD
Is there one state-of-the-art treatment for depression?
Vitamin D Augmentation in Major Depression With Comorbid Vitamin D Deficiency
D for Depression? Researchers performed a 12-week, randomized, double-blind placebo-controlled trial of vitamin D augmentation for major depression with vitamin D deficiency.
A Single Dose of Psilocybin for Treatment-Resistant Depression
A single dose of psilocybin could help patients with treatment-resistant depression, according to a new study.